Welcome! The Bloomington Life Sciences Partnership is a collaborative effort dedicated to continued life sciences business growth in greater Bloomington, Indiana - a nationally recognized leading metro area in medical devices, contract pharma, biotechnology, basic research and life sciences workforce development.

News

BioConvergence Expands Services and Rebrands as Singota™ Solutions

Posted June 9, 2016

BioConvergence Expands Services and Rebrands as Singota™ Solutions

BioConvergence LLC, a life sciences contract service provider, makes a big change to respond to client needs. BLOOMINGTON, INDIANA (PRWEB) JUNE 09, 2016 – BioConvergence LLC announces a major initiative that includes a transition to a new name and an expansion of its services consistent with the company’s strategic plan and vision of CEO Alisa Wright. “We continually seek new ways to improve patients’ lives by helping our clients accelerate their product development process. This has been our mission from the start of the company ten years ago. This project, like our past expansions, fills a critical need expressed by our clients,” Wright said. The service expansion will require construction of clean rooms and installation of equipment necessary to fill injectable drug products into vials, syringes, and cartridges for clients in the pharmaceutical industry. This added capability complements the company’s existing services that span from formulation development to finished product for use in clinical trials. Senior Director of Operations Brent Lieffers said, “This expansion not only brings innovative technology to our clients, but also creates new employment opportunities in our community.” Concurrent with the expansion, the company name will transition to Singota™ Solutions. This reflects the company’s continued growth as a Contract Development and Manufacturing Organization (CDMO) and its commitment to accelerating the drug development process through innovative solutions. Lynn Coyne, president of the Bloomington Economic Development Corporation, commented, “This major expansion of an already successful life science company signals a very bright future for BioConvergence. BioConvergence’s creativity and innovation make it a market leader and we are grateful that BioConvergence has chosen to stay and grow in Monroe County.” Wright added, “On behalf of everyone at the company, we are excited about the future, and we deeply appreciate the support from the local community.” The company will make further announcements as to its progress over the coming months. About BioConvergence BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, labeling and kitting, and supply chain services. Headquartered in Bloomington, Indiana, BioConvergence has over 50 employees with many years of valuable experience in the pharmaceutical and biotechnology industries. The unique E-Transparency® System provides transparency and flexibility to clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.bioc.us. Please follow and like...

read more

BioConvergence® Celebrates 10 Year Anniversary

Posted April 21, 2016

BioConvergence® Celebrates 10 Year Anniversary

BioConvergence® Celebrates 10 Year Anniversary Bloomington, IN (April 21, 2016) – BioConvergence is pleased to announce it has reached its tenth year of operations. Starting in 2006, the company was a service provider to the pharmaceutical and biopharmaceutical sectors, and since then has expanded to the animal health, diagnostics, and medical device industries. BioConvergence is a women-owned, small business operating in a 72,000 square foot facility in Bloomington, Indiana.   The company’s service lines include drug formulation development, analytical methods development and testing activities, formulation and filling, labeling and kitting operations, and supply chain management. BioConvergence provides these services to firms of all sizes, from virtual organizations to large pharma, and to companies with needs around the globe. Over the years, the company has played important roles in the development of several products on the market today. BioConvergence focuses on innovation, flexibility, responsiveness, and building customized solutions for clients, always keeping the patient in mind.   “We made it!” Alisa Wright, founder and CEO said. “The past 10 years have been wonderful due to the privilege and trust our clients extended to us and the valuable results our team delivered to our clients. We will continue to expand our capabilities to provide the customer care and tangible value our clients depend on. Thank you to all of our clients, vendors, board members, family, and friends for all the support. We are proud to be a part of the Bloomington community.”   For more information on BioConvergence, visit www.bioc.us/ or contact BioConvergence at solutions@bioc.us. Please follow and like...

read more

GMP Weigh & Dispense Operations Personnel: “They’re Indispensable!”

Posted April 18, 2016

GMP Weigh & Dispense Operations Personnel: “They’re Indispensable!”

Weigh & dispense operations play a crucial part in pharmaceutical material handling and storage. Weigh & dispense is the process of removing precisely specified amounts of bulk raw material from their source container, and dispensing them into aliquots of specific quantities into other containers. Dispensed quantities are used to provide samples for R&D work, laboratory testing (for material identity, purity, and compendial test data), and material allotments for manufacturing and reference standards. The Weigh & Dispense Operational Environment Large-scale weigh and dispense operations have diverse operational requirements. The volume of requests for dispensed materials can fluctuate widely from day to day. Client schedules change constantly. The ability to dispense many different types of materials in diverse material forms (tablets, liquids, powder), amounts (milligrams to kilograms), and containers (small vials to drums) is essential. Weight tolerances of dispensed amounts vary and can be challenging to meet. A variety of equipment and techniques are used – different personal protective equipment (PPE), balances, utensils, isolators, glove boxes and bags, powder dispensers, peristaltic pumps and tubing, to name a few. Materials have diverse safe handling requirements. Constant, disciplined, and demanding techniques for cleaning and handling are required to prevent cross contamination. Materials being processed may be sensitive to static electricity, lighting, temperature, and humidity. The technical and capital investments required to provide these services with high efficiency and near-zero error rates are easy to appreciate. What may not be recognized, but may be just as critical to success, is the human side of the equation. The Human Element Engineering and IT support, facilities design, equipment, safety programs, proper PPE, standard operating procedures, and personnel training programs are all key in providing a foundation from which to accommodate the complexities of GMP weigh & dispense operations discussed above. But the human factor is vital in making all of these resources work together to provide a weigh & dispense service that can meet these demanding needs. Effective weigh & dispense personnel have specific expertise and well-honed technical skills across a wide range of instrumentation, documentation, material handling techniques, equipment, safety, and cross-contamination prevention procedures. There also are “soft” skills and attributes that are needed in a successful weigh and dispense operation:   Flexibility — Highly variable weigh and dispense operations require people who thrive in an operational environment that is constantly changing. Balance — Successful weigh and dispense specialists need the ability to carry out work procedures in roles that can be repetitive and tedious, requiring focus and great attention to detail. People who can perform well in highly variable and highly detailed functions are difficult to find. Communication — Weigh & dispense specialists are in a position to provide valuable observations, individually and in collaboration with each other. Their suggestions to engineering, maintenance, and operations are invaluable in improving quality, providing better service to clients, and making processes safer, more accurate, and more cost effective. Their ability to absorb and thoroughly understand both verbal and written work instructions is important to a successful operation. Their ability to communicate the complexities of their operation to client-facing personnel in a clear and understandable manner is extremely helpful in devising solutions for client and operational requirements. Mindset, Self-Motivation, and Patience — Just working in the clean rooms of weigh & dispense facilities takes people with a special...

read more

Come to Begin 2 Biz, Business Mentoring Open Hours, at WestGate

Posted

Come to Begin 2 Biz, Business Mentoring Open Hours, at WestGate

Are you a small business owner, an entrepreneur, or are you interested in learning more about starting your own business? Begin 2 Biz is the perfect event for you. Several regional organizations that help businesses develop have come together to provide free open hours to people just like you! Whether you don’t know where to start or you are a seasoned business professional, these regional groups know how to handle your questions no matter what stage of growth your business is in. Here is a list of the participating organizations that will be in attendance: Indiana Procurement Technical Assistance Center (PTAC) Indiana Small Business Development Center (ISBDC) Indiana Small Business Innovative Research (SBIR) Program IODD’s Technology Commercialization Program Radius Indiana NSWC Crane Division’s Small Business and Technology Transfer programs Bloomington Economic Development Corporation Ivy Tech’s Gayle & Bill Cook Center for Entrepreneurship (Bloomington) Purdue University’s Technical Assistance Program (TAP) Purdue Foundry University of Southern Indiana’s Center for Applied Research WestGate Academy Conferencing & Training Center Begin to Biz will take place April 19th from 9:00 AM – 12:00 PM at The Lock & Key in WestGate Academy. This event will occur every third Tuesday of the month. Begin 2 Biz is free and open to the public to attend. No appointments are necessary.  The Lock & Key is a collaborative coworking space that is currently accepting members. Located just outside of NSWC Crane, it is the perfect place to work, meet, start, or grow your business. WestGate Academy 13598 East WestGate Drive Odon, IN 47562 For more information, please contact Sarah Miller at sarah.miller@stimulusengineering.com. Please follow and like...

read more

Bloomington Innovation Conference to highlight IU research with potential commercial applications

Posted March 31, 2016

Bloomington Innovation Conference to highlight IU research with potential commercial applications

Bloomington Innovation Conference to highlight IU research with potential commercial applications March 29, 2016 FOR IMMEDIATE RELEASE BLOOMINGTON, Ind. — Researchers from across all academic disciplines at Indiana University Bloomington will present information about projects that have potential commercial applications at the second annual Bloomington Innovation Conference on March 31.   The Johnson Center for Innovation and Translational Research organizes the event, which will take place 9 a.m. to 6:30 p.m. EDT in the Frangipani Room and Georgian Room, Indiana Memorial Union, Biddle Hotel and Conference Center, 900 E. Seventh St., Bloomington. Attendance is limited, and registration is required.   JCITR works with faculty and researchers throughout the IU Bloomington campus to identify discoveries that hold commercial potential and protect intellectual property. It also assists with grant applications, identifying industry partners, negotiating industry contracts, project-management support and increased use of core IU facilities by industry partners. Director Keith R. Davis believes researchers will benefit by attending the conference.   “Presenters will have the opportunity to receive valuable feedback on their work through discussions with attendees from both the Bloomington campus and regional industry partners,” Davis said. “We see this conference as a key activity of the JCITR and hope we can foster more industry-academic collaborations in Bloomington.”   Scheduled speakers include Michael Hiles, vice president for research and development and chief scientific officer, Cook Biotech Inc.; Maria J. Blanco, director, discovery chemistry research & technologies, Eli Lilly & Co.; Adam Zlotnick, professor, Department of Molecular and Cellular Biochemistry and co-founder, Assembly Biosciences; and IU innovators who received funding through the JCITR Translational Research Pilot Grant Program. Media Contacts Steve Martin Office 317-278-1505 stgmart@iu.edu Source: http://news.indiana.edu/releases/2016/03/bloomington-innovation-conference-highlights-research.shtml Please follow and like...

read more

Translational Research Pilot Grant Program

Posted February 11, 2016

Translational Research Pilot Grant Program

To All IUB Faculty Members:   The Johnson Center for Innovation and Translational Research is pleased to announce the second year of Translational Research Pilot Grants. This pilot grant program has been established to fund the completion of proof of concept projects that support the development of research projects with industry partners, the establishment of new companies, or strengthen patent applications based on IUB discoveries.   Eligible Projects   All projects in any discipline directly related to moving IUB research or scholarly activities closer to commercialization are eligible. Projects must be based on discoveries that have been submitted to the IURTC in the form of an Invention Disclosure (http://iurtc.iu.edu/forms/index.shtml). Project proposals may be submitted by any IUB faculty member. Project budgets up to $25,000 will be considered and can be used to support research in the Principal Investigators laboratory, or for purchased services from IU core facilities or external vendors.   Proposal Reviews   Pilot Grant applications will be assessed for their scientific merit, the potential to significantly enhance the commercial development of the new discovery, and the potential for the creation of new intellectual property.   Application Due Date   April 1, 2016 Funding will be available June 1, 2016   Instructions for applying can be accessed on the JCEB website: http://jcitr.indiana.edu/opportunities.shtml   We are available to meet with you to discuss potential projects and assist with the filing of the Invention Disclosure. We encourage you to take advantage of this new funding opportunity!   Regards, Keith   Keith R. Davis, Ph.D. Director The Johnson Center for Innovation and Translational Research Simon Hall, Room 100A 212 S. Hawthorne Drive Indiana University, Bloomington, IN 47405 Office: 812-856-4805 Email: keirdavi@indiana.eduJCITR   For more information, see Pilot Grant Program Description-2016 Please follow and like...

read more

Biosciences Institute Adds Research Fellow

Posted January 28, 2016

Biosciences Institute Adds Research Fellow

INDIANAPOLIS – The Indiana Biosciences Research Institute has named its first Indiana Research Fellow. Indiana University Center for Diabetes and Metabolic Diseases Director Raghu Mirmira will also serve as the institute’s interim scientific director. Mirmira is also a professor of pediatric diseases, director of IU’s Herman B. Wells Center’s Pediatric Diabetes Research Group and director of the Medical Scientist Training Program for M.D. and Ph.D. students. He earned his bachelor’s, M.D. and Ph.D. degrees from the University of Chicago. As part of his new role with IBRI, he will work with Chief Executive Officer David Broecker to recruit additional research scientists, set up research operations and begin project work. Broecker calls Mirmira a “unique and talented researcher with a track record of building nationally-recognized research centers.” The $360 million institute was launched in 2013, through a partnership among private sector companies, academic institutions and the state of Indiana. Funding has come from companies and organizations including Eli Lilly and Co. (NYSE: LLY), Dow AgroSciences, Lilly Endowment Inc., Roche Diagnostics and Indiana University Health. The state has targeted the planned 60-acre 16 Tech innovation district as a permanent location for the institute. To read more on this, visit Inside Indiana Business or the Indiana Biosciences Research Institute. Please follow and like...

read more

Johnson Center for Innovation and Translational Research announces new name, expanded mission

Posted November 20, 2015

Johnson Center for Innovation and Translational Research announces new name, expanded mission

FOR IMMEDIATE RELEASE BLOOMINGTON, Ind. — A monthslong effort to shift the Johnson Center for Entrepreneurship in Biotechnology’s mission is complete, as it now boasts a new name, a broader base of campus constituents and an updated website. The organization is now known as the Johnson Center for Innovation and Translational Research, or JCITR. The new name was approved by the Indiana University Board of Trustees in October and recently made official by President Michael A. McRobbie, said Keith R. Davis, the center’s director. The move not only addressed a need to lessen confusion with its cross-campus counterpart, the Johnson Center for Entrepreneurship and Innovation at the Kelley School of Business. It also reflects an expanded mission to serve all schools, departments and disciplines throughout the Bloomington campus, rather than only those ventures related to biotechnology or other fields within the College of Arts and Sciences. Yet JCITR’s core directive is unchanged. It aims to boost the participation of faculty, researchers and students in translational research and the commercialization of research discoveries by working with industry partners and creating new companies. “Our new name truly captures the core focus of our mission to enhance innovation across the Bloomington campus and will provide an identity for our unique position within IU’s research community,” Davis said. “We hope faculty will come to recognize JCITR as the place where they can get hands-on assistance with building a translational research program and commercializing their discoveries.” Vice Provost for Research Rick Van Kooten said the move reinforces IU’s commitment through its Bicentennial Strategic Plan to build a prosperous and innovative Indiana, in part by establishing a culture of “building and making” statewide. “I am truly excited that the expertise of the Johnson Center is now broadening to encompass the entire Bloomington campus,” Van Kooten said. “Innovation and translational research are key drivers of research excellence. The skills and services offered through JCITR are invaluable to IU researchers, particularly as we move forward with our Grand Challenges program and a new Emerging Areas of Research program.” Members of JCITR’s staff, or “discovery team,” work to make it easy and efficient for faculty to bring their ideas or inventions to market while continuing to focus on their core strengths in basic research. Such duties include: Working with faculty to identify current and new research that can attract commercial contracts or be translated into products that may lead to the launch of Spin Up companies or startup ventures; Collaborating with the IU Research and Technology Corp. and Office of Research Administration to help faculty submit grant applications; Identifying industry partners and negotiating industry contracts in concert with the ORA; Working with the IURTC to help faculty protect their intellectual property and establish companies when appropriate; Providing project-management support for faculty involved in industry-funded research; Assisting with communications by reporting to industry partners during projects; Developing strategies to increase the use of core university facilities by industry partners. “Tier 1 research universities like IU are the primary drivers of discovery in today’s world,” said Larry Singell, executive dean of the College of Arts and Sciences. “Translating research into practical, useful forms is one of our essential contributions to a better world. So JCITR is central to IU’s mission to generate research in ways that benefit the state, the U.S....

read more

Novo Nordisk to acquire Calibrium LLC and MB2 LLC

Posted August 28, 2015

Novo Nordisk to acquire Calibrium LLC and MB2 LLC

Acquisition expands Novo Nordisk’s portfolio of projects within diabetes and obesity Bagsværd, Denmark, 27 August 2015 – Novo Nordisk today announced that it has entered into a definitive agreement under which Novo Nordisk will acquire Calibrium LLC and MB2 LLC, two privately held biopharmaceutical research companies based in Indiana, US. Formed in 2013 and 2014, respectively, Calibrium and MB2 are focused on developing a portfolio of novel drug candidates for the treatment of diabetes and related metabolic diseases. The acquisition will expand Novo Nordisk’s portfolio of projects and intellectual property rights within diabetes and obesity and provide a basis for expanding Novo Nordisk’s research presence in the US. Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk says: “We are always on the lookout for ways to strengthen our leadership position within therapeutic proteins. This research team has demonstrated world-class capabilities in protein design and created a project portfolio of innovative product leads that fit very well with our aspirations within diabetes and obesity.” Dr Richard DiMarchi, chief scientific officer and co-founder of Calibrium and MB2 says: “It’s an honour to join the global Novo Nordisk research community. Their intense focus on metabolic diseases, which over the years has led to numerous breakthrough proteinbased medicines, aligns perfectly with my career-long priorities. I’m optimistic that together we can create novel, transformative therapies in the fight against the global epidemic of diabetes and obesity.” The parties have agreed not to disclose the financial details of the transactions. The closing of the transaction is subject to US regulatory approval and is expected to occur during the third quarter of 2015.   About Calibrium and MB2 Calibrium is an emerging biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. Calibrium was co-founded by Fritz French, chief executive officer, and Richard DiMarchi, PhD, chief scientific officer. MB2 is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class, mixed agonist drugs for the treatment of diabetes and obesity. MB2 was co-founded by Kent Hawryluk, chief executive officer and Richard DiMarchi, PhD, chief scientific officer. Both companies are privately held and located in Carmel, IN, US. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 39,700 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube Please follow and like...

read more

Sintact Medical Systems Receives NSF SBIR Grant

Posted August 12, 2015

Sintact Medical Systems Receives NSF SBIR Grant

Phase I grant will advance development of Sintact’s surgical film, which prevents internal scar formation Bloomington, IN – August 12, 2015 – Sintact Medical Systems, a startup developing an implantable film that prevents internal scar formation following surgery, announced today that the company was selected for a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant. In addition to the $150,000 Phase I grant, Sintact was awarded $50,000 in matching funds from Elevate Ventures in partnership with the Indiana Economic Development Corporation (IEDC).   The collective funds will contribute to the company’s ongoing testing and development of a non-resorbable film designed to separate and protect internal organs from scar formation and scar-related defects—complications that frequently occur after a number of common surgeries.   “It’s exciting to get this kind of validation and support from an organization like the NSF SBIR program, not to mention the additional contribution from Elevate Ventures and the IEDC,” said Sintact CEO Erik Robinson. “These organizations have provided an incredible opportunity that will enable us to make substantial progress toward bringing our technology to market and ultimately improving patients’ lives.”   Phase I of the NSF SBIR grant program is designed as a “proof-of-concept” grant, which can be followed by a larger development grant of $750,000. For the initial phase, Sintact plans to conduct a three-month animal study—a longer version of a study Robinson performed during his doctoral work at Northwestern University in collaboration with Ann & Robert H. Lurie Children’s Hospital of Chicago, which demonstrated a reduction in scar formation of 86 percent.   In addition to seeking out grant funding, Robinson has advanced the commercialization of Sintact’s technology by participating in various programs that support startups, which he feels ultimately helped them secure the grant.   “We’ve been fortunate to get involved in a number of programs that exist to support companies like ours, and these have been an invaluable resource,” Robinson said. “Not only have they helped connect us to mentors, investors and experts in our field who have been instrumental in our growth, but they’ve also helped position us as an attractive investment and a strong candidate for grants like this one.”    Sintact was a member of the 2014 class of Health Wildcatters, a Dallas-based healthcare startup accelerator program. The company has also been supported by VentureWell, an organization out of Massachusetts that helps commercialize innovations developed at colleges and universities, and iBIO Institute’s PROPEL Center, a Chicago-based effort to increase success rates of life science startups.     “It’s wonderful to see Sintact making such great progress since the program,” said Health Wildcatters CEO Hubert Zajicek. “They have all the elements for success, so it’s exciting to watch all those elements come together as they get closer to bringing their technology to the patients who can benefit from it.”   Phase I of the NSF SBIR grant ends December 31, 2015. Upon completion of Phase I, Sintact will report results to be considered for the additional Phase II funding.   For more information on Sintact and their surgical film technology, visit sintactmed.com.    About Sintact Medical Systems Sintact Medical Systems, Inc. develops non-resorbable films that separate adjacent organs from adhering to each other after surgery. The Sintact Film™ acts as a scar preventative barrier separating organ and tissue...

read more